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Background. Chronic cytomegalovirus (CMV) infection has been associated with immunosenescence and im-
munoactivation in the general population. In human immunodeﬁciency virus type 1 (HIV-1)–infected people, CMV
coinfection, in addition to residual HIV replication and microbial translocation, has been proposed as a key factor in
sustaining immune activation, even in individuals with a controlled HIV load.
Methods. Patients from the ICONA Study with at least 1 CMV immunoglobulin G (IgG) test available without
active CMV disease were included in the analysis. AIDS-deﬁning event or AIDS-related death and severe non–
AIDS-deﬁning event or non–AIDS-related death were taken as clinical progression end points. Independent predic-
tors of CMV were identiﬁed by multivariable logistic regression. Probabilities of reaching the end points were
estimated by survival analyses.
Results. A total of 6111 subjects were included, of whom 5119 (83.3%) were CMV IgG positive at baseline.
Patients with CMV IgG positivity at baseline were more likely to develop a severe non–AIDS-deﬁning event/
non–AIDS-related death (adjusted hazard ratio [HR], 1.53 [95% conﬁdence interval {CI}, 1.08–2.16]. In particular,
CMV seropositivity was an independent risk factor for cardiovascular and cerebrovascular diseases (adjusted HR,
2.27 [95% CI, .97–5.32]).
Conclusions. In our study population, CMV/HIV coinfection was associated with the risk of severe non–
AIDS-deﬁning events/non–AIDS-related death, especially with cardiovascular and cerebrovascular events, indepen-
dently of other prognostic factors. This ﬁnding supports a potential independent role of CMV coinfection in
vascular/degenerative organ disorders in HIV-infected subjects.
Keywords. CMV infection; severe non–AIDS-deﬁning events; cardiovascular/cerebrovascular events; HIV
infection; mortality; morbidity.
Cytomegalovirus (CMV) is a beta human herpesvirus
with a worldwide spread. CMV infection is often
asymptomatic and acute and is followed by lifelong per-
sistence of CMV in a latent stage in immunocompetent
subjects but with potentially severe consequences in im-
munocompromised patients [1].
In the general population, CMV seroprevalence rang-
es from 50% to 90%, with the majority of individuals
being infected in adulthood; the chance of acquiring
CMV infection rises by 1% per year of age [2]. The
infection rate is also inﬂuenced by socioeconomic status
[3] and geographical location [4, 5]. In HIV-infected
subjects, CMV is highly prevalent (from 75% to 90%),
particularly among homosexual men [6, 7].
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CMV has been associated with the development of cardiovas-
cular diseases (CVDs) [8, 9] and all-cause and CVD-related
mortality in the general population [10].
Human immunodeﬁciency virus (HIV) infection seems to be
an independent risk factor for atherosclerosis and end-organ
disease, even in patients receiving antiretroviral therapy
(ART) [11, 12], and CMV coinfection might contribute to accel-
erate cardiovascular complications in HIV-positive patients.
Recently, several studies focused on the relationship between
CMV/HIV coinfection and CVD. Hsue et al have shown that
a large T-lymphocyte response to CMV is linked with an in-
creased intima media thickness in HIV-infected patients and
with atherosclerosis in both HIV-negative and HIV-positive
subjects [9]. Parrinello et al have observed that CMV immuno-
globulin G (IgG) antibody levels are associated with subclinical
atherosclerosis in HIV aviremic women [13]. Moreover, in
solid-organ-transplant recipients, the prophylactic treatment
for preventing CMV reactivation reduces the risk of atheroscle-
rosis, suggesting a potential pharmacological preventive action
in this special setting [14].
Furthermore, CMV has been linked with other diseases char-
acterized by chronic immune activation, such as dementia, can-
cer, and osteoporosis [15]. Finally, CMV seropositivity belongs
to a cluster of immune factors constituting an immune risk
proﬁle associated with all-cause mortality in elderly individuals
[16, 17].
The aim of the present study was to evaluate the seropreva-
lence and predictors of CMV infection in a prospectively fol-
lowed Italian national cohort of HIV-infected subjects.
Moreover, we studied whether CMV-seropositive status was as-
sociated with the risk of developing either AIDS-deﬁning events
or severe non–AIDS-deﬁning events and AIDS-related death or
non–AIDS-related death.
METHODS
Study Population
The study population was selected from the ICONA Founda-
tion Study cohort. The ICONA study is an Italian multicenter
prospective observational study of HIV-1–positive persons that
was set up in April 1997. At the time of analysis, 10 129 subjects
naive to antiretroviral drugs at baseline were enrolled after pro-
viding written informed consent via a standard form.
Demographic, clinical, and laboratory data, as well as thera-
pies, are collected for all participants and recorded in an online
database (http://www.icona.org). All data are updated at the
occurrence of any clinical event and, in their absence, at least
every 6 months. Details of the cohort and data collection have
been previously reported [18].
Patients included in this analysis had at least 1 CMV IgG test
available and, at the time of the test, were free from any reported
CMV-related disease, were free from any non–AIDS-deﬁning
events listed below, and had at least 1 follow-up visit after the
ﬁrst CMV IgG test result was recorded. The date of the database
freezing for statistical analysis was 1 October 2012. Baseline for
the analysis was set as the date of the ﬁrst CMV IgG test. CMV
serological testing was performed in the different centers, using
commercially available kits.
The ICONA study was approved by the institutional review
boards or ethics committees of each clinical site and of the Uni-
versity of Milan.
Statistical Analysis
Patients with CMV IgG–positive and CMV IgG–negative re-
sults of serological tests were compared in terms of baseline
characteristics by χ2 analysis or the Wilcoxon test, as appropri-
ate. Factors independently associated with CMV positivity at
baseline were identiﬁed by a multivariable logistic regression
model. The following variables were considered a priori as
potential cofactors/confounders and were included in the mul-
tivariable logistic model, using a 1-step manual adjustment: age,
sex, ethnicity (white vs other), hepatitis C virus (HCV) antibody
positivity, hepatitis B virus (HBV) surface antigen (HBsAg)
positivity, mode of HIV transmission (male-male sex, hetero-
sexual sex, injection drug use, and other/unknown), time
from HIV diagnosis, Centers for Disease Control (CDC) disease
stage (A/B vs C), use of ART, CD4+ T-cell count, and CD4+/
CD8+ T-cell ratio. For the categorical variables, persons with
missing data were included in a separate group, categorized as
“unknown,” to minimize the selection bias.
We then investigated time to AIDS-deﬁning event/AIDS-
related death and, in a separate model, time to severe non–
AIDS-deﬁning event/non–AIDS-related death. AIDS-deﬁning
events were deﬁned according to the 1993 CDC classiﬁcation
[19]. Among severe non–AIDS-deﬁning events we included
non–AIDS-deﬁningmalignancies, cardiovascular and cerebrovas-
cular events (myocardial infarction, coronary artery bypass graft,
coronary angioplasty, carotid endarterectomy, non–myocardial
infarction coronary disease, stroke, cerebral hemorrhage,
peripheral vascular disease, and pulmonary hypertension),
nonvascular neurological diseases (peripheral neuropathies,
myelitis, epilepsy, and non–HIV-associated neurocognitive dis-
orders), and end-stage renal disease [20]. Event data collection
in the ICONA cohort follows the operative procedure protocol
D:A:D MOOP, version 1.4. Non–AIDS-related deaths included
all deaths due to the listed severe non–AIDS-deﬁning events.
We decided to exclude hepatic failure, liver cancer, and liver-
related deaths that are clearly related to HCV/HBV coinfections
and for which the impact of CMV could be at best summative
more than resulting from a direct action.
Because we used composite end points, the time of the event
was deﬁned as the earliest day at which one of the event-deﬁning
conditions occurred. Only 1 event per person was counted (the
ﬁrst occurrence). We used a competing-risk approach: the
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follow-up of patients who experienced an event other than the
one under evaluation as well as any events not of interest, were
censored at the end of follow-up. Competing-risk survival anal-
yses using Kaplan–Meier estimates were used to estimate the
cumulative probability of developing an AIDS-deﬁning event/
AIDS-related death and severe non–AIDS-deﬁning event/non–
AIDS-related death by a certain time after the date of the ﬁrst
CMV IgG test. The log–rank test was used to compare the
risk of developing the end point, according to the CMV coinfec-
tion status. Multivariable Cox proportional hazards survival anal-
ysis was used to assess the association between CMV coinfection
at baseline and each end point; the same baseline characteristics
as for the multivariable logistic regression were considered a pri-
ori as possible confounders and were included in the multivari-
able model, using a 1-step manual adjustment, with the exception
of the CD4+/CD8+ T-cell ratio and with the addition of base-
line HIV RNA levels. In an additional model, ART use, HIV
RNA levels, and CD4+ T-cell counts were also handled as
time-dependent covariates. To test whether smoking habits
could possibly inﬂuence the risk of severe non–AIDS-deﬁning
events/non–AIDS-related deaths, a further analysis was con-
ducted that included the subset of patients for whom this infor-
mation was available; covariates included were the same as those
used in the main analysis. Cox-Snell residuals were used to test
the overall ﬁt of the Cox models, and the plots of the integrated
hazard based on these residuals against the hazard rates estimated
from the model showed a 45-degree slope, suggesting that the
models were appropriate.
RESULTS
Cross-sectional Analysis
A total of 10 129 HIV-positive subjects were enrolled in the
ICONA Foundation cohort at the time of analysis: 6111 met
the speciﬁed criteria and were included in the study. Patients
excluded from the analyses were comparable to the whole
cohort in terms of demographic characteristics (data not
shown). Most of the patients underwent CMV serological test-
ing at the time of enrollment in the cohort, whereas 10% were
tested after a median time of 17 months (interquartile range
[IQR], 6–45 months).
A total of 5119 subjects were positive for CMV IgG, giving a
prevalence of 83.3%. The baseline characteristics of the popula-
tion, according to CMV serological status, are shown in Table 1.
CMV-infected patients, compared with uninfected patients,
were older (median age, 36 years [IQR, 32–42 years] vs 35
years [IQR, 31–40 years]; P < .0001), had a lower prevalence
of positivity for HCV antibody (32.7% vs 37.6%; P = .0028),
had a lower prevalence of advanced HIV disease (AIDS,
10.8% vs 13.3% [P = .02]; CD4+ T-cell count, 448 cells/µL
Table 1. Demographic and Clinical Characteristics, According to Cytomegalovirus (CMV) Serostatus at Baseline, Among Human
Immunodeﬁciency Virus (HIV)–Infected Patients
Characteristic Total Population (n = 6111) CMV Positive (n = 5119) CMV Negative (n = 992) P Valuea
Age, y 36 (32–42) 36 (32–42) 35 (31–40) <.0001b
Female sex 1745 (28.6) 1446 (28.3) 299 (30.1) .23
Ethnicity .06
White 5588 (91.4) 4658 (90.9) 930 (93.8)
Black 285 (4.7) 252 (4.9) 33 (3.3)
Asian 33 (0.6) 30 (0.6) 3 (0.3)
Hispanic 145 (2.3) 125 (2.4) 20 (2.0)
HCV positive 2047 (33.5) 1674 (32.7) 373 (37.6) .0028
HBsAg positive 330 (5.4) 284 (5.6) 46 (4.7) .24
Mode of HIV transmission .0002
Injection drug use 1829 (29.9) 1495 (29.2) 334 (33.7)
Heterosexual sex 2337 (38.2) 1942 (37.9) 395 (39.8)
Male-male sex 1564 (25.6) 1363 (26.6) 201 (20.3)
Time since HIV diagnosis, y 1 (0–7) 1 (0–7) 2 (0–7) .40b
AIDS 683 (11.2) 551 (10.8) 132 (13.3) .02
Receiving ART 755 (12.4) 637 (12.4) 118 (11.9) .63
CD4+ T-cell count, cells/µL 443 (270–634) 448 (279–636) 417 (225–620) .0017b
CD4+/CD8+ T-cell ratio 0.46 (0.27–0.71) 0.46 (0.27–0.70) 0.49 (0.27–0.77) .010b
HIV RNA load, log10 copies/mL 3.74 (2.62–4.60) 3.74 (2.62–4.59) 3.76 (2.65–4.66) .47
b
Data are median (interquartile range) or no. (%) of subjects.
Abbreviations: ART, antiretroviral therapy; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus.
a By the χ2 test, unless otherwise indicated.
b By the Wilcoxon test for independent variables.
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[IQR, 279–636 cells/µL] vs 417 cells/µL [IQR, 225–620 cells/µL;
P = .017]), but had a lower CD4+/CD8+ T-cell ratio (0.46 [IQR,
0.27–0.70] vs 0.49 [IQR, 0.27–0.77]; P = .010).
In a multivariable logistic analysis, age (per 10-year increase;
adjusted odds ratio [OR], 1.42 [95% conﬁdence interval {CI},
1.33–1.52]; P < .0001), male-male sex (vs injection drug use;
adjusted OR, 1.67 [95% CI, 1.36–2.06]; P = .0001), and a higher
CD4+ T-cell count at baseline (per 100 cells/µL increase; adjusted
OR, 1.04 [95% CI, 1.02–1.06]; P = .0005) were associated with
CMV seropositivity, whereas white ethnicity (adjusted OR,
0.51 [95% CI, .39–.66]; P = .001) and a higher CD4+/CD8+
T-cell ratio (adjusted OR, 0.85 [95% CI, .77–.95]) were negative-
ly associated with CMV seropositivity.
Time to AIDS-Deﬁning Event/AIDS-Related Death
During a median follow-up period of 5.2 years (IQR, 1.79–9.66
years), 490 patients reached the end point of an AIDS-deﬁning
event/AIDS-related death: 413 experienced an AIDS-deﬁning
event, and 77 died of an AIDS-related cause. The most prevalent
events were esophageal candidiasis (14.8%), Pneumocystis jiro-
vecii pneumonia (10.6%), tuberculosis (13.1%; 6.8% pulmonary
and 6.3% extrapulmonary), and Kaposi sarcoma (8.5%). There
were not signiﬁcant differences in the distribution of AIDS-
deﬁning events/AIDS-related deaths between CMV-seropositive
and CMV-seronegative subjects (data not shown).
The 10-year estimated proportion experiencing an AIDS-
deﬁning event/AIDS-related death was 10.9% (95% CI, 8.3%–
13.5%) for CMV-negative individuals and 12.4% (95% CI,
11.1%–13.6%) for CMV-positive individuals (P = .67, by the
log–rank test; Figure 1A). CMV seropositivity was not a pre-
dictor of AIDS-deﬁning event/AIDS-related death by multivar-
iable Cox analysis. As expected, classical factors such as AIDS at
baseline (adjusted hazard ratio [HR], 2.42 [95% CI, 1.90–3.04];
P < .0001) and higher HIV RNA load (per 1 log10 copies/mL
increase; adjusted HR, 1.23 [95% CI, 1.14–1.33]; P < .0001)
had a role in predicting AIDS-deﬁning events/AIDS-related
deaths, whereas higher CD4+ T-cell counts (per 100 cells/µL in-
crease) at baseline were a protective factor (adjusted HR, 0.80
[95% CI, .76–.84]; P < .0001; Figure 2).
Time to Severe Non–AIDS-Deﬁning Event/Non–AIDS-Related
Death
During a median follow-up period of 5.6 years (IQR, 2.03–10.06
years), 338 patients reached the end point: 326 experienced
severe non–AIDS-deﬁning events, and 12 died of non–AIDS-
related causes. All events are listed in Table 2.
The 10-year estimated proportion reaching the end point was
6.2% (95% CI, 4.1%–8.3%) for CMV-negative subjects and 8.9%
(95% CI, 7.7%–10.1%) for CMV-positive subjects (P = .0058, by
the log–rank test; Figure 1B). After control for a number of
potential confounders by Cox regression analysis, CMV seropo-
sitivity remained an independent risk factor for severe non–
AIDS-deﬁning events/non–AIDS-related death, with an
adjusted HR of 1.53 (95% CI, 1.08–2.16; P = .016). Other pre-
dictive factors were older age (adjusted HR, 1.65 for each 10-
year increase [95% CI, 1.47–1.85]; P < .0001), and AIDS at
baseline (adjusted HR, 1.49 [95% CI, 1.09–2.03]; P = .011;
Figure 2). In a different model that considered ART use,
Figure 1. Kaplan–Meier survival curve for AIDS-deﬁning event/AIDS-related death and severe non–AIDS-deﬁning event/non–AIDS-related death, by
cytomegalovirus (CMV) serostatus. A, CMV-infected patients did not show an increased risk of developing AIDS-deﬁning events/AIDS-related death.
B, CMV-infected patients had an increased risk of developing severe non–AIDS-deﬁning events/non–AIDS-related death. Abbreviation: IgG, immunoglobulin G.
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HIV RNA level, and CD4+ T-cell count as time-dependent
confounders, CMV positivity still remained an independent
risk factor for non–AIDS-deﬁning events (adjusted HR, 1.53
[95% CI, 1.08–2.16]; P = .015).
We did not detect signiﬁcant associations between CMV
seropositivity and non–AIDS-related malignancies (adjusted
HR, 1.98 [95% CI, .73–5.36]; P = .17) or nonvascular neurolog-
ical diseases (adjusted HR, 0.94 [95% CI, .54–1.62; P = .82) by
multivariable analysis. Conversely, CMV seropositivity was an
independent risk factor for cardiovascular and cerebrovascular
disease, with an adjusted HR of 2.27 (95% CI, .97–5.32;
P = .058).
To determine a possible confounding effect of tobacco
smoking, we analyzed information about smoking habits at
baseline, which was available for 3470 of 6111 patients
(56.8%). The proportions of cigarette smokers among CMV-
positive and CMV-negative individuals were comparable
(51.2% vs 50.1%; P = .64). After adjustment for smoking status,
CMV coinfection remained associated with a higher hazard of
severe non–AIDS-deﬁning events/non–AIDS-related death (ad-
justed HR, 1.77 [95% CI, .92–3.40]; P = .08). The marginally
nonsigniﬁcant association was probably due to the smaller sam-
ple size, as suggested by the increase in the CI. Further, being a
cigarette smoker at baseline was independently associated with
severe non–AIDS-deﬁning events/non–AIDS-related death (ad-
justed HR, 1.53 [95% CI, .07–2.21]; P = .02); the estimates of the
other variables included were comparable to those from the
main analysis (data not shown).
Finally, we performed an additional analysis to eliminate a
possible effect of other viral comorbid conditions, using the
main multivariable model but excluding all HCV antibody–
positive and/or HBsAg-positive subjects. A total of 189 events
in 3865 patients were observed. Results conﬁrmed that CMV
positivity was strongly associated with severe non–AIDS-
deﬁning events/non–AIDS-related death (adjusted HR, 2.43
[95% CI, 1.38–2.49]; P = .0021).
Figure 2. Factor predictive of severe non–AIDS-deﬁning events/non–AIDS-related death and AIDS-deﬁning events/AIDS-related death, by Cox regression
analysis. Cytomegalovirus (CMV) seropositivity, AIDS at baseline, and older age were independent risk factors for severe non–AIDS-deﬁning events/non–
AIDS-related death (right). Moreover, AIDS, CD4+ T-cell count, and human immunodeﬁciency virus (HIV) RNA load at baseline were independent risk factors for
AIDS-deﬁning events/AIDS-related death (left). Data are expressed as adjusted hazard ratios (HRs) and 95% conﬁdence intervals (CIs). *P < .01. Abbreviations:
Ab, antibody; ART, antiretroviral therapy; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; IDU, injection drug use; IgG, immunoglobulin G.
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DISCUSSION
The extended access to ART has led to a remarkable improve-
ment in terms of mortality and morbidity, thereby increasing
the life expectancy of HIV-infected individuals [21]. Conse-
quently, patterns of morbidity and mortality among HIV-
infected subjects receiving ART are changing, with an increase
in the proportion of deaths due to non–HIV-related disorders,
including cardiovascular disease, liver disease, and non–AIDS-
deﬁning cancers [22, 23]. Lower CD4+ T-cell count, anemia, and
uncontrolled viral load, along with the classical potentially
modiﬁable risk factors, such as cigarette smoking, diabetes,
and hypertension, seem to play a driving role in developing se-
vere non–AIDS-deﬁning events, although available data are
partially contrasting [24, 25]. Studies on modiﬁable and non-
modiﬁable risk factors for non–AIDS-deﬁning events in HIV-
infected persons are still an important unmet research issue.
The aim of this study was to determine the seroprevalence of
CMV antibodies among HIV-positive subjects enrolled in the
ICONA cohort and to deﬁne the impact of CMV serostatus
on AIDS and severe non–AIDS-deﬁning events/non–AIDS-
related death. The seroepidemiology of CMV was examined
in 6111 HIV-positive patients (the CMV IgG test is not a man-
datory test for HIV-infected people, so it is up to the treating
center to decide whether to perform it at enrollment or later),
and 83.3% were coinfected with CMV and HIV. The seropreva-
lence in HIV-infected people has been already described, but
very few data are available from cohort studies. A higher rate
of CMV infection has been found in HIV-infected patients,
compared with the HIV-negative population, with a seropreva-
lence peaking at 90% in the French Seroco group [26].
In our cohort, the seroprevalence was lower than that in other
cohorts, possibly because of differences in HIV transmission
routes, age, or nationality [27]. Predictive factors of CMV sero-
positivity were older age, nonwhite ethnicity, male-male sex as
transmission category, higher CD4+ T-cell count at baseline,
and lower CD4+/CD8+ T-cell ratio. Regarding the acquisition
age of CMV infection, a gradual increase in risk during life
has been demonstrated, with the highest risk of CMV serocon-
version being in individuals aged 30–35 years [2].
In the general population, CMV seroprevalence tends to be
highest in South America, Africa, and Asia and lowest inWestern
Europe and the United States. Some of the nonwhite groups had
CMV seroprevalences approaching 100% [27–29]. In agreement
with these ﬁndings, in our cohort of HIV-positive individuals,
the seroprevalence was lower in white individuals, compared
with black Africans, Asian, and Hispanics, even if the proportion
of nonwhite individuals was small in this patient set.
Higher prevalence rates among homosexual men can be
attributed to the already described increased risk of exposure as-
sociated with receptive anal intercourse [30]. In our cohort, a
higher CD4+ T-cell count and a lower CD4+/CD8+ T-cell ratio
were independent predictors for CMV seropositivity, but com-
parison of the CMV-positive and CMV-negative groups revealed
that the median CD4+ T-cell count and CD4+/CD8+ T-cell ratio
were very similar and that the increased risk was minimal.
We could not ﬁnd an association between CMV infection
and the development of AIDS-deﬁning events/AIDS-related
death. It is important to note that patients with active CMV dis-
ease were excluded. Similar results were reported in cohorts of
HIV-infected hemophiliacs [31, 32]. In the pre-ART era, CMV
infection was associated with disease progression, especially in
Table 2. Severe Non–AIDS-Deﬁning Events and Non–AIDS-
Related Death During Follow-up
Outcome No. (%)a
Severe non–AIDS-defining event 326 (96.4)
Cardiovascular/cerebrovascular diseases 91 (28.2)
AMI/coronaropathy 35 (38.4)
Ischemic stroke 4 (4.4)
Hemorrhagic stroke 2 (2.2)
Peripheral vasculopathy 16 (17.6)
Dilated cardiomyopathy 3 (3.3)
Heart failure 7 (7.7)
Acute pulmonary edema 1 (1.1)
Pulmonary hypertension 10 (11.0)
Other cardiovascular diseases 13 (14.3)
Cancer 117 (36.2)
Hodgkin lymphoma 22 (18.8)
Lung 13 (11.1)
Head, neck 12 (10.3)
Bladder 10 (8.5)
Colorectal 7 (5.9)
Breast 5 (4.3)
Anal 4 (3.4)
Kidney 3 (2.6)
Melanoma 3 (2.6)
Seminoma 3 (2.6)
Metastasis 3 (2.6)
Prostate 2 (1.7)
Others 30 (25.6)
Neurologic events 115 (35.6)
Peripheral neuropathy 79 (68.7)
Epilepsy 8 (6.9)
Cerebral atrophy 4 (3.5)
Encephalopathy (not ADC) 4 (3.5)
Other neurologic symptoms 9 (7.8)
Other neurological disorders 11 (9.6)
End-stage renal disease 3 (0.9)
Non–AIDS-related death 12 (3.6)
AMI 2 (16.7)
Cardiovascular/cerebrovascular disease 6 (50.0)
Neoplasia 4 (33.3)
Abbreviations: ADC, AIDS dementia complex; AMI, acute myocardial infarction.
a The percentage was calculated in comparison with each parent group.
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subjects with detectable CMV viremia, but this scenario
changed after ART introduction. In fact, the natural history
of CMV has changed in terms of viral replication and reactiva-
tion owing to the suppression of HIV replication and improved
immunity among patients. However, chronic CMV infection
could maintain its ability to act as a cofactor for other disorders
[33, 34].
In line with this, CMV/HIV-coinfected subjects showed an
approximately 50% higher risk of severe non–AIDS-deﬁning
events/non AIDS death. Indeed, after control for a number of
potential confounders, CMV infection was still an independent
risk factor for severe non–AIDS-deﬁning events, suggesting a
potential role of CMV infection in the morbidity and mortality
of this population. The association was particularly evident for
cerebrovascular and cardiovascular events, which is in agree-
ment with several studies reporting an increased risk of all-
cause and cardiovascular-related mortality in the CMV-infected
HIV-negative population [8–10]. To exclude the effect of other
HCV and HBV coinfections, a supplementary analysis was
performed only in HCV antibody–negative and/or HBsAg-
negative subjects: this conﬁrmed the increased risk of develop-
ing severe non–AIDS-deﬁning events/non-AIDS-related death
for CMV-infected patients.
To our knowledge, this is the ﬁrst HIV cohort study in which
CMV/HIV-coinfected individuals were compared to HIV-
monoinfected individuals in terms of morbidity and mortality,
resulting in a higher risk for severe non–AIDS-deﬁning events/
non–AIDS-related death in CMV/HIV-coinfected subjects.
When we consider as end-point the different disease catego-
ries, CMV seropositivity independently increased the risk of
developing cardio-cerebral vascular diseases reaching a AHR
of 2.27, even if the P value was .058. Multiples lines of evidence
suggest a direct or indirect role of CMV infection in the devel-
opment of cardiovascular disorders. In the HIV-negative pop-
ulation, an association between CMV seropositivity or the CMV
IgG antibody level and cardiovascular disease [35, 36] and
cardiovascular mortality [37–39] has been reported. In a
mouse model, murine CMV infection caused a signiﬁcant
increase in arterial blood pressure in vivo, independent of a
high-cholesterol diet, and the virus has been found in athero-
sclerotic plaques of the mouse aorta [40]. CMV seropositivity
has been associated with subsequent cardiac mortality only in
patients with an interleukin 6–mediated inﬂammatory response
[41]. In our study, we did not compare patients according to the
level of CMV antibodies. Instead, we analyzed a population of
patients with or without CMV infection. Whether higher IgG
antibody levels represent a marker of more pronounced or
more frequent subclinical CMV reactivation from latency re-
mains a matter of debate [38]; moreover, the choice of a quan-
titative CMV IgG titer cutoff is often arbitrary. In our study,
blood pressure, lipids, diet, and soluble markers of inﬂamma-
tion were not considered, but we were able to study the impact
of CMV infection on clinical events in HIV-positive with or
without CMV infection, according to their serostatus.
In HIV-infected individuals, a higher prevalence of atheroscle-
rosis has been demonstrated, even after control for traditional risk
factors [11, 42]. Previous studies have associated such higher rates
of atherosclerosis with HIV itself, the use of ART [43], higher lev-
els of T-cell activation [44, 45], or dysfunctional dendritic cell
homing [46]. It is now widely accepted that the initiation and pro-
gression of atherosclerotic lesions involves a chronic inﬂammato-
ry response, even if the source of the inﬂammation is still unclear.
Some evidence suggests that CMV may contribute to inﬂamma-
tion in plaques [40]. Long-term successfully treated HIV-infected
patients have been shown to present high levels of CMV-speciﬁc
effector cells, similar to those observed in the elderly population
[47], suggesting an important role of the CMV-speciﬁc inﬂam-
matory response in immunosenescence and non–AIDS-related
morbidity and mortality. In fact, in ART recipients, a robust,
age-independent anti-CMV T-cell response has been shown to
alter T-cell reconstitution, owing to thymic involution or mobili-
zation of resources, inducing a senescent phenotype [47].
Moreover, CMV infection not only induces a large fraction of
antigen-speciﬁc T cells [48, 49], it is also associated with a higher
frequency of subclinical atherosclerosis in HIV-infected women
and men [9, 13]. Together, this suggests a potential role for
CMV-speciﬁc immunity in the atherosclerosis observed in pa-
tients infected with HIV. Future studies will be needed to clarify
the immunological mechanisms involved in this phenomenon
and to better understand the interaction between CMV and
HIV in the pathogenesis of severe non–AIDS-deﬁning events.
Finally, to adjust our analyses for the effect of potential con-
founders linked to cardiovascular and cerebrovascular risk, we
analyzed smoking status, which was reported only by 56.8% of
patients. The association between CMV seropositivity and
severe non–AIDS-deﬁning events/non–AIDS-related death
showed the same trend, although it did not reach statistical sig-
niﬁcance, presumably because of the reduced sample size.
A possible limitation of our study is that CMV testing was
done only once for most patients, usually at enrollment, which
therefore excludes the inﬂuence of new incident CMV infec-
tions. However, we can assume from previous observations
that the seroconversion rate during follow-up is low, around
1% per 1 year of age, therefore minimizing its inﬂuence. More-
over, we assumed that chronic CMV infection would take
several years to inﬂuence the analyzed clinical outcomes.
In summary, our ﬁndings from the ICONA cohort suggest
that chronic CMV infection increases the risk of severe non–
AIDS-deﬁning events/non–AIDS-related death. Cardiovascular
and cerebrovascular events seem to be strictly linked to CMV
seropositivity, conﬁrming the potential atherogenic role of
CMV in HIV-infected subjects.
In the management of patients with HIV infection, CMV se-
rostatus it is not routinely evaluated, probably because of the
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lack of an obvious intervention for CMV-seropositive individu-
als. Despite this, on the basis of our ﬁndings, CMV-seropositive
status should be considered a negative prognostic factor, and
closer monitoring for cardiovascular and cerebrovascular dis-
eases, as well as management of other modiﬁable risk factors,
could be considered in CMV/HIV-coinfected individuals. The
inclusion of this parameter in available prognostic scores [50]
should be evaluated.
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